Gregoriou O, Vitoratos N, Papadias C, Konidaris S, Costomenos D, Chryssikopoulos A
2nd Department of Obstetrics and Gynecology, University of Athens, Areteion Hospital, Greece.
Maturitas. 1997 Jun;27(2):187-91. doi: 10.1016/s0378-5122(97)00036-4.
The aim of this study is to assess the effect of Tibolone (Livial) on uterine fibroids in postmenopausal women.
This study included 40 naturally postmenopausal women with at least one uterine fibroid measuring > 20 mm. All of theme were scanned by transvaginal ultrasonography. Patients were randomized into two groups. Group A (n = 20) were treated with Tibolone 2.5 mg daily for 1 year and group B (n = 20) did not received therapy. The size of the uterine fibroids was reevaluated on the end of the treatment.
No statistically significant difference was found in the mean volume of fibroids before and after treatment with Tibolone. The administration of Tibolone resulted in an increase of fibroid volume in three patients, whereas it remained constant in the majority of the patients (70%) and decreased in three patients.
Our results suggest that treating menopausal symptoms with Tibolone does not affect preexisting asymptomatic uterine fibroids.
本研究旨在评估替勃龙（利维爱）对绝经后妇女子宫肌瘤的影响。
本研究纳入了40名自然绝经且至少有一个直径大于20mm子宫肌瘤的妇女。所有患者均接受经阴道超声检查。患者被随机分为两组。A组（n = 20）每天服用2.5mg替勃龙，持续1年；B组（n = 20）不接受治疗。治疗结束时重新评估子宫肌瘤的大小。
服用替勃龙治疗前后，肌瘤的平均体积无统计学显著差异。服用替勃龙后，3例患者肌瘤体积增大，大多数患者（70%）肌瘤体积保持不变，3例患者肌瘤体积减小。
我们的结果表明，用替勃龙治疗绝经症状不会影响已存在的无症状子宫肌瘤。
